Skip to main content
. 2019 Mar 14;14(3):e0213929. doi: 10.1371/journal.pone.0213929

Fig 1. Decision analytic model.

Fig 1

Visual representation of the decision analytic model, with the inclusion of GSTP1 c.313 A>G genotyping for patient selection, prior to treatment initiation. In the genotyping branch, patients with AG or GG for GSTP1 c.313 A>G (high risk) would receive fosaprepitant as a primary preventive measure. Patients with low risk (AA) genotype would receive fosaprepitant only in the presence of grades 3 or higher CINV, for subsequent cycles. The standard branch of the model represents the usual practice, without prior patient genotype assessment, including fosaprepitant since D1. CRT: chemoradiation.